Mutru, Mikaela
Kivelä, Pia
Ollgren, Jukka
Liitsola, Kirsi
Gissler, Mika
Aho, Inka
Funding for this research was provided by:
Gilead Nordic Fellowship Programme
University of Helsinki including Helsinki University Central Hospital
Article History
Received: 2 September 2022
Accepted: 6 February 2023
First Online: 18 February 2023
Declarations
:
: The study protocol and methods were approved by the Finnish Institute for Health and Welfare’s Data and Analytics Unit (THL/1572/6.02.00/2019). A review from an ethics committee is not required for research on humans that uses only register data according to Finnish national guidelines (Finnish National Board on Research Integrity TENK: The national ethical principles of research with human participants and ethical review in the human sciences in Finland,ExternalRef removed[CitationRef removed]).For this study, informed consent is deemed unnecessary in accordance with national legislation that permits the use of retrospective health register data for scientific research without informed consent provided that appropriate measures to protect personal data are taken (Act on Secondary Use of Health and Social Data, 552/2019,ExternalRef removed[CitationRef removed] and Act on the Institute for Health and Welfare, 668/2008,ExternalRef removed[CitationRef removed]). All methods were performed in accordance with the ethical guidelines of the Finnish National Board on Research Integrity, national legislation and the institutional guidelines of the Finnish Institute for Health and Welfare.
: Not applicable.
: The authors declare no conflicts of interest directly related to the study. PK and IA have received personal fees for Advisory Board participation, lectures and travel expenses from GSK, Gilead and Merck.